Introduction Intimate partner violence and abuse (IPVA) is a public health crisis with long-term implications for an individual's mental and physical health. IPVA can result in head and neck trauma, including oral injuries, placing dentists in a unique position to be able to identify at-risk patients. It is therefore important to understand any barriers dentists may experience when supporting IPVA patients.Aims The aim of this study was to explore whether dentists and dental students are prepared to support patients with lived experience of IPVA.Method This study adopted a qualitative cross-sectional research design using focus groups and interviews. Data were collected using the principles of grounded theory and analysed using thematic analysis.Results Data were collected from 14 dentists and 22 dental students showing that they did not feel confident or prepared in identifying and responding to patients they suspected were experiencing IPVA. Barriers included a lack of practical knowledge and fear of 'getting it wrong', resulting in professional paralysis.Conclusion Improving current safeguarding educational frameworks at both the undergraduate and postgraduate stage could be key to improving the confidence and practical knowledge of dental practitioners.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/s41415-024-8059-3 | DOI Listing |
Transl Oncol
January 2025
Johns Hopkins Greenberg Bladder Cancer Institute, Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA. Electronic address:
Bladder cancer (BLCA) genomic profiling has identified molecular subtypes with distinct clinical characteristics and variable sensitivities to frontline therapy. BLCAs can be categorized into luminal or basal subtypes based on their gene expression. We comprehensively characterized nine human BLCA cell lines (UC3, UC6, UC9, UC13, UC14, T24, SCaBER, RT4V6 and RT112) into molecular subtypes using orthotopic xenograft models.
View Article and Find Full Text PDFInteract J Med Res
January 2025
University of California, San Francisco, Department of Laboratory Medicine, San Francisco, US.
Physicians could improve the efficiency of the healthcare system if a reliable resource were available to aid them in better understanding, selecting, and interpreting the diagnostic laboratory tests. It has been well established and widely recognized that (a) laboratory testing provides 70-85% of the objective data that physicians use in diagnosis and treatment of their patients, (b) orders for laboratory tests in the U.S.
View Article and Find Full Text PDFHepatology
January 2025
Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.
Background And Aims: Alcohol-related liver disease (ALD) is one of the leading causes of severe liver disease with limited pharmacological treatments for alcohol-related steatohepatitis (ASH). CD44, a glycoprotein mainly expressed in immune cells, has been implicated in multiple inflammatory diseases but has never been studied in the ALD context. We therefore studied its contribution to ASH development in mice and its expression in ALD patients.
View Article and Find Full Text PDFBlood
January 2025
H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have been used to risk-stratify patients with MDS to guide treatment strategies. In higher-risk MDS, the therapeutic approach is geared toward delaying leukemic transformation and prolonging survival.
View Article and Find Full Text PDFBlood
January 2025
Fred Hutchinson Cancer Center, Seattle, Washington, United States.
Sclerosis is a highly morbid manifestation of chronic GVHD (cGVHD), associated with distressing symptoms and significant long-term disability. A patient-reported outcome measure (PRO) for cGVHD-associated sclerosis is essential to advance therapeutic trials. We aimed to develop a PRO for adults with cGVHD-associated sclerosis and evaluate and refine its content validity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!